Oncologist fascinated by emerging technologies and therapeutics in healthcare. Views are my own.
Philadelphia, PA
Joined April 2016
- Tweets639
- Following2.1K
- Followers770
- Likes5.5K
Ben Miron retweeted
💡Will #ctDNA serve as a treatment response biomarker in metastatic cancers?
Here’s a thorough evaluation in @CCR_AACR from the RECIST working group, looking at the next steps towards using ctDNA for novel early endpoints in clinical trials and beyond. 👉 doi.org/10.1158/1078-0432.CC…
Ben Miron retweeted
📢Close fup, limited censoring shows true OS durability in this small vanguard cohort of met #bladdercancer pts rx w EVP. Particularly impressive in cis inelig who often have comorbidities. Kudos to teams that invest in/prioritize long term follow up of metastatic trials! #ESMO24
We presented the 5-year OS update for pts who are cis-ineligible w/met UC treated in EV-103 cohort A/Dose Esc with EV/pembro: 41% of patients are alive at 5 years! (Historical data <5% in a similar pt population). If this holds up in EV302, it is truly a game changer! #ESMO2024
Ben Miron retweeted
TP53:
- Discovered 45 years ago, most cited gene all time
- No therapies
- 500 million people currently living will die of TP53 mutant cancers without new therapies
Our Preprint:
- A general strategy for TP53 missense mutant cancers (majority) with prototype small molecules
Ben Miron retweeted
Hundreds of Jewish students at @Columbia just published one of the most incredible student letters I have ever read.
It's not only magnificently written, but it also clearly articulates their experiences on campus for the past six months.
Their letter tells the story of what's it like being a Jewish student right now better than any professor like myself could ever do.
Please take 4-5 minutes to read their letter.
Give Jewish students a voice.
docs.google.com/document/u/1…
Ben Miron retweeted
A lot about anti-NECTIN4 ADC Enfortumab vedotin (EV) beyond UC at #ASCO24! @ASCO
Data of multi-cohort EV-202 (NCT04225117) will be released!
➡️Excited to see the single-agent activity of EV in biomarker-unselected (NECTIN4 status not required!)
- gastric/esophageal cancer (Abstract # 4046)
- NSCLC (Abstract # 8585)
- TNBC & HR+/HER2- breast cancer (Abstract # 1005)
➡️Our recent data highlights the correlation between NECTIN4 targetability and EV response, which is consistent with findings obtained for other ADCs, such as the Her-2-targeting ADC trastuzumab-deruxtecan within DESTINY-PanTumor02 Phase II
ascopubs.org/doi/abs/10.1200… @JCO_ASCO &
aacrjournals.org/clincancerr… @AACR @CCR_AACR
➡️Future biomarker research should be performed to correlate NECTIN4 expression with EV response across entities! @Markuseckstein3
➡️Urgently needed for ADC precision oncology!
@OncoAlert @PTarantinoMD @urotoday @Uroweb @imedverse @drenriquegrande (# 4046)
Ben Miron retweeted
Congratulations to the amazing @skopetz for his @AACR Waun Ki Hong Award. Eye opening listening to his presentation on Adaptive Resistance in BRAF- and KRAS-mutated #colorectalcancer #crcsm #AACR24 #AACRSSP @MDAndersonNews
Ben Miron retweeted
The #OncoAlertTOPtweet at Day 1 of #EAU24
Post By @OncoAlert 🚨GU Faculty @tompowles1 🇬🇧
Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24. Do we need to give adjuvant therapy to those as such low risk?
Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24. Do we need to give adjuvant therapy to those as such low risk?
Ben Miron retweeted
It‘been a while, but 🎉🔬 The 17th episode is out.
The last entity we tackled was the „incarnation“ of hot/inflamed urothelial carcinomas🔥🔥🔥🔥
But what do you know about PD-L1 testing ?
Today @MattGalsky presented important data of CheckMate274 at #EAU24. PD-L1 positive patients benefit significantly from adjuvant Nivolumav treatment.
👉 In Europe adjuvant Nivolumab is only approved for PD-L1 positive patients.
👉 PD-L1 testing is thus important and its importance might increase with current neoadjuvant studies reading out soon!
But what does PD-L1 positive mean? Read below in following posts 👇
@AmerUrological, @Uroweb, @ASCO, @PathSoc. #Uropathology #urothelial #cancer #MedicalInnovation @NEJM @JAMANetwork @JAMA_current @OncoAlert @onkowissen @imedverse @Histo_Journal @niklas_kluemper #pathtwitter
@brookmans76 @PGrivasMDPhD @DrYukselUrun @shilpaonc @drenriquegrande @amerseburger
So insightful! Never understood it as well until this explanation! Worth reading if you too have been stumped by the lack of consistency of clinical data when you group it together.
Now you understand that MIBC with TPS of 10% has a CPS of at least 10!
But: It could have no positive immune cells!
However, a tumor that is negative on tumor cells could have a CPS of 100 and a TPS of 0%.
When thinking of that a bit you will
Immediately understand that the ALGORITHMS make the difference and not the ASSAYS!
👉 And: PD-L1 positive/negative populations divided by a cut off e.g., CPS10 (Pembro/Ambassador) versus TPS1 %(Nivo/Checkmate274) can be completely different !!!!
I hope this helps a bit ! And ask questions if not ☺️.
At least one thing is clear: PD-L1 testing is not dead, it is returning ! And maybe even more on the near future.
Ben Miron retweeted
This trial will answer several important questions- do we need to escalate therapy to get better outcomes in the highest risk patients, and can we de-escalate in those who are lower risk. @MattGalsky @apolo_andrea @tompowles1 @sonpavde @TiansterZhang
For #TrialTuesday, .@MattGalsky @IcahnMountSinai leads @ALLIANCE_org A032103 (MODERN) to test the role of DNA released from tumor cells into the blood in guiding the use of #immunotherapy after bladder removal for #bladdercancer treatment: bit.ly/Alliance-A032103 @bladdercancerus
Ben Miron retweeted
We report for the 1st time therole of tumor fraction in ctDNA in pts w/ mUC in RW @FoundationATCG
👉 ass. w/ clinico-path features & rwPFS
👉prognostic biomarker
👉may help personalize tx
👉prospective trials needed
@myESMO @ElsevierNews @CleClinicMD
protect-us.mimecast.com/s/jG…
Ben Miron retweeted
Excellent/elegant work by @BenMironMD @shilpaonc et al. Agree that ctDNA holds high promise in UC. Its clinical utility regarding decision making needs well-designed trials with relevant endpoints @MattGalsky @HsiehLab @JoshMeeks @Parminder1699 @GavinHa @FaltasLab @Uromigos – at Seattle, WA
We report for the 1st time therole of tumor fraction in ctDNA in pts w/ mUC in RW @FoundationATCG
👉 ass. w/ clinico-path features & rwPFS
👉prognostic biomarker
👉may help personalize tx
👉prospective trials needed
@myESMO @ElsevierNews @CleClinicMD
protect-us.mimecast.com/s/jG…
Ben Miron retweeted
From NYSE: The co-founder of Scion Life Sciences on coming out of stealth mode and the new $310 million venture fund announced this week.
Full video: biotechtv.com/post/scion-lif…
Ben Miron retweeted
❤️ Love our @FoxChaseCancer home team - couldn't ask for a better crew! Some not pictured, others covering back home, many @FCUroOnc contributions to #GU24 – at San Francisco, CA
Ben Miron retweeted
NECTIN4 amplification predicts response to Enfortumab vedotin in mUC! It occurs frequently across solid tumors (app. 25% of mUC)➡️potential tumor-agnostic biomarker for NECTIN4-targeting therapies! Happy to share our poster K17 @ASCO #GU24! @Markuseckstein3 @OncoAlert @urotoday
Ben Miron retweeted
Grateful for the unwavering support of my mentors @DrChoueiri and @VanAllenLab
It was a pleasure to present part of our work with @Chrislabaki1 @ZiadBakouny @BenMironMD @MattZibelman @ERPlimackMD
Check out our poster # 459 at @ASCO #GU24 on Saturday!
Brilliant work by @eddy_saad on multi-omic characterization of acquired resistance to ICI in mRCC!
@VanAllenLab @DanaFarber_GU @OncLive
Ben Miron retweeted
Congrats @BenMironMD on presenting tumor fraction in ctDNA as a prognostic biomarker in mUC
@RyonGraf @cnscicom @FoxChaseCancer @CleClinicMD @ERPlimackMD @FoundationOne
Ben Miron retweeted
Love seeing our @FoxChaseCancer crew at #ESMO2023 #ESMO23 ! @HosseinBorghaei @BenMironMD @NVijayvergiaMD – at Madrid, Spain
Ben Miron retweeted
Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023
